Roquefort Therapeutics (LSE:ROQ) ROCE % : -25.07% (As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Roquefort Therapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Roquefort Therapeutics's annualized ROCE % for the quarter that ended in Jun. 2024 was -25.07%.

Roquefort Therapeutics ROCE % Historical Data

The historical data trend for Roquefort Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roquefort Therapeutics ROCE % Chart

Roquefort Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

ROCE %

-27.57

-29.12

Roquefort Therapeutics Semi-Annual Data
	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
ROCE %	Get a 7-Day Free Trial			-16.64	-46.62	-26.32	-31.76	-25.07

Roquefort Therapeutics ROCE % Calculation

Roquefort Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-1.932	/	( ( (7.768 - 0.28)	+	(6.089 - 0.307) )	/ 2 )
	=	-1.932	/	( (7.488	+	5.782)	/ 2 )
	=	-1.932	/	6.635
	=	-29.12 %

Roquefort Therapeutics's ROCE % of for the quarter that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	-1.378	/	( ( (6.089 - 0.307)	+	(6.074 - 0.863) )	/ 2 )
	=	-1.378	/	( ( 5.782	+	5.211 )	/ 2 )
	=	-1.378	/	5.4965
	=	-25.07 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

Roquefort Therapeutics (LSE:ROQ) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Roquefort Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of Roquefort Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Roquefort Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Roquefort Therapeutics PLC (LSE:ROQ) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

85 Great Portland Street, First Floor, London, GBR, W1W 7LT

Website

https://www.roquefortplc.com

Roquefort Therapeutics PLC is engaged in pursuing opportunities to acquire medical biotechnology businesses. Its product portfolio consists of MDK Antibody, MDK Oligo, MDK mRNA, STAT-6 siRNA, and MK Cell. The principal activity of the Company is to develop pre-clinical next-generation medicines focused on hard-to-treat cancers.

Roquefort Therapeutics Headlines

No Headlines